xRead - September 2022

Wise et al.

Page 415

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Study design Study groups Clinical endpoint Conclusion

Significant improvement of allergoid over allergen.

Significant improvement in symptom scores in the treatment group.

Significant improvement in subjects with severe symptoms and long

standing symptoms with treatment.

Efficacious, benefits lasted for 2 more seasons.

No difference in primary endpoint after 1 season, chest symptoms were better in the treatment group after the second season.

Significant improvement in nasal, ocular, and combined symptom and medication scores in treatment group.

Significant reduction in symptoms, improved conjunctival tolerance,

increase in IgG, and decreased skin reactivity.

Daily symptom and medication scores

Rhinoconjunctivitis symptoms after exposure in a chamber

Symptom and medication scores

Symptoms, immune changes, adverse reactions

Primary: symptom and medication scores; Secondary:

tissue markers of inflammation.

Symptom scores, medication scores, skin reactivity, IgG and IgE antibodies

Symptoms, conjunctival provocation, skin-prick tests, IgG and IgE levels

3 Mite allergoid SCIT 50,000 AUeq/mL;

4 Mite allergoid SCIT 100,000 AUeq/mL; 5 Placebo

Norman et al. 1590 1981 2b Open trial 1 Allergoid ragweed (formaldehyde-treated); 2 Allergen ragweed Adjuvant constructs

Patel et al. 1066 2014 1b RDBPCT 1 Four weekly injections of short ragweed pollen allergoid adsorbed to L-tyrosine monophosphoryl lipid A; 2 Placebo

Dubuske et al. 1598 2011 1b RCT 1 Pre-seasonal grass modified allergen tyrosine adsorbate monophosphoryl lipid A; 2 Placebo

Creticos et al. 1596 2006 1b RDBPCT 1 Ragweed Amb a 1-phosphorothioate oligodeoxyribonucleotide conjugate (TLR-9 agonist); 2 Placebo

Tulic et al. 1610 2004 1b RCT 1 Amb a 1-oligodeoxyribonucleotide conjugate; 2 Placebo

Drachenberg et al. 1611 2001 1b RDBPCT 1 Pre-seasonal tyrosine-adsorbed glutaraldehyde modified grass pollen extract containing 3 deacylated monophosphoryl lipid; 2 Placebo

Senti et al. 1612 2009 2b Open trial 10 weekly injections of dust mite with A-type CpG oligodeoxynucleotides with virus-like particles

Study Year LOE

DBPCT = double blond placebo controlled trial; Ig = immunoglobulin; LOE = level of evidence; QOL = quality of life; RCT = randomized controlled trial; RDBPCT = randomized double blind placebo controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SCIT = subcutaneous immunotherapy; SLIT = sublingual immunotherapy; TLR = toll-like receptor.

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.